ARGX-117, ARGX-113
ARGX-999-2-MG-20001
Phase 2 small_molecule active
Quick answer
ARGX-117, ARGX-113 for AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis, MG, gMG is a Phase 2 program (small_molecule) at Argenx with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Argenx
- Indication
- AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis, MG, gMG
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active